Alliancebernstein L.P. Sells 210,262 Shares of Humana Inc. (NYSE:HUM)

Alliancebernstein L.P. cut its stake in shares of Humana Inc. (NYSE:HUM) by 58.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 151,095 shares of the insurance provider’s stock after selling 210,262 shares during the period. Alliancebernstein L.P. owned about 0.13% of Humana worth $38,334,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. FPC Investment Advisory Inc. purchased a new stake in Humana during the fourth quarter valued at $27,000. Centricity Wealth Management LLC purchased a new stake in shares of Humana during the 4th quarter valued at about $30,000. LFA Lugano Financial Advisors SA lifted its stake in shares of Humana by 56.3% in the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock worth $32,000 after purchasing an additional 45 shares during the period. OFI Invest Asset Management purchased a new position in shares of Humana in the fourth quarter worth approximately $33,000. Finally, Atwood & Palmer Inc. grew its position in Humana by 64.5% during the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock valued at $39,000 after buying an additional 60 shares during the period. 92.38% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on HUM shares. Truist Financial lifted their price target on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. Barclays boosted their price target on Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a report on Thursday, February 13th. StockNews.com cut Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, March 18th. Morgan Stanley decreased their target price on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research report on Tuesday, February 18th. Eighteen research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $280.17.

Humana Stock Down 4.6 %

Shares of HUM opened at $253.37 on Friday. The business’s 50 day simple moving average is $267.58 and its 200-day simple moving average is $271.85. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The stock has a market capitalization of $30.58 billion, a price-to-earnings ratio of 25.46, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62.

Humana (NYSE:HUM) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, equities analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 annualized dividend and a yield of 1.40%. Humana’s payout ratio is currently 35.58%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.